Does Cyp3a Inducers Interact with Selpercatinib?
CDI records a moderate classification for Cyp3a Inducers and Selpercatinib. The stored summary is: Concomitant use decreases selpercatinib plasma concentrations, which may reduce anti-tumor activity. Avoid coadministration. The mechanism involves cyp3a induction decreases selpercatinib plasma concentrations. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Moderate
- Selpercatinib Class
- Kinase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
CYP3A induction decreases selpercatinib plasma concentrations
What To Tell Your Doctor or Pharmacist
If you are taking Cyp3a Inducers and your doctor is considering prescribing Selpercatinib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider